NYSEAMERICAN:NTN

NTN Buzztime Competitors

$6.43
+1.29 (+25.10 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.86
Now: $6.43
$7.10
50-Day Range
$1.88
MA: $2.11
$2.42
52-Week Range
$0.94
Now: $6.43
$7.76
Volume4.70 million shs
Average Volume1.63 million shs
Market Capitalization$19.14 million
P/E RatioN/A
Dividend YieldN/A
Beta0.72

Competitors

NTN Buzztime (NYSEAMERICAN:NTN) Vs. EDSA, CLRB, PULM, MNPR, GTBP, and AZRX

Should you be buying NTN stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to NTN Buzztime, including Edesa Biotech (EDSA), Cellectar Biosciences (CLRB), Pulmatrix (PULM), Monopar Therapeutics (MNPR), GT Biopharma (GTBP), and AzurRx BioPharma (AZRX).

NTN Buzztime (NYSEAMERICAN:NTN) and Edesa Biotech (NASDAQ:EDSA) are both small-cap consumer discretionary companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for NTN Buzztime and Edesa Biotech, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NTN Buzztime0000N/A
Edesa Biotech0000N/A

Institutional and Insider Ownership

6.3% of NTN Buzztime shares are owned by institutional investors. Comparatively, 1.4% of Edesa Biotech shares are owned by institutional investors. 24.2% of NTN Buzztime shares are owned by company insiders. Comparatively, 61.4% of Edesa Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares NTN Buzztime and Edesa Biotech's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NTN Buzztime$19.81 million0.97$-2,050,000.00N/AN/A
Edesa Biotech$330,000.00227.62$-6,360,000.00($0.74)-7.70

NTN Buzztime has higher revenue and earnings than Edesa Biotech.

Volatility & Risk

NTN Buzztime has a beta of 0.72, indicating that its share price is 28% less volatile than the S&P 500. Comparatively, Edesa Biotech has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500.

Profitability

This table compares NTN Buzztime and Edesa Biotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NTN Buzztime-61.42%-162.54%-49.94%
Edesa Biotech-1,928.79%-110.02%-78.55%

Summary

NTN Buzztime beats Edesa Biotech on 7 of the 10 factors compared between the two stocks.

Cellectar Biosciences (NASDAQ:CLRB) and NTN Buzztime (NYSEAMERICAN:NTN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

Risk & Volatility

Cellectar Biosciences has a beta of 1.67, suggesting that its stock price is 67% more volatile than the S&P 500. Comparatively, NTN Buzztime has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500.

Profitability

This table compares Cellectar Biosciences and NTN Buzztime's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cellectar BiosciencesN/A-129.44%-90.76%
NTN Buzztime-61.42%-162.54%-49.94%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Cellectar Biosciences and NTN Buzztime, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cellectar Biosciences00403.00
NTN Buzztime0000N/A

Cellectar Biosciences presently has a consensus price target of $3.6667, suggesting a potential upside of 147.75%. Given Cellectar Biosciences' higher possible upside, research analysts clearly believe Cellectar Biosciences is more favorable than NTN Buzztime.

Earnings and Valuation

This table compares Cellectar Biosciences and NTN Buzztime's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellectar BiosciencesN/AN/A$-14,090,000.00($1.84)-0.80
NTN Buzztime$19.81 million0.97$-2,050,000.00N/AN/A

NTN Buzztime has higher revenue and earnings than Cellectar Biosciences.

Institutional & Insider Ownership

12.7% of Cellectar Biosciences shares are owned by institutional investors. Comparatively, 6.3% of NTN Buzztime shares are owned by institutional investors. 5.3% of Cellectar Biosciences shares are owned by company insiders. Comparatively, 24.2% of NTN Buzztime shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Cellectar Biosciences beats NTN Buzztime on 7 of the 11 factors compared between the two stocks.

NTN Buzztime (NYSEAMERICAN:NTN) and Pulmatrix (NASDAQ:PULM) are both small-cap consumer discretionary companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, analyst recommendations and profitability.

Institutional and Insider Ownership

6.3% of NTN Buzztime shares are owned by institutional investors. Comparatively, 19.3% of Pulmatrix shares are owned by institutional investors. 24.2% of NTN Buzztime shares are owned by insiders. Comparatively, 4.3% of Pulmatrix shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares NTN Buzztime and Pulmatrix's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NTN Buzztime$19.81 million0.97$-2,050,000.00N/AN/A
Pulmatrix$7.91 million9.17$-20,600,000.00($0.80)-1.61

NTN Buzztime has higher revenue and earnings than Pulmatrix.

Analyst Ratings

This is a summary of recent ratings for NTN Buzztime and Pulmatrix, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NTN Buzztime0000N/A
Pulmatrix00103.00

Pulmatrix has a consensus target price of $10.00, indicating a potential upside of 675.19%. Given Pulmatrix's higher probable upside, analysts clearly believe Pulmatrix is more favorable than NTN Buzztime.

Volatility & Risk

NTN Buzztime has a beta of 0.72, indicating that its share price is 28% less volatile than the S&P 500. Comparatively, Pulmatrix has a beta of 1.66, indicating that its share price is 66% more volatile than the S&P 500.

Profitability

This table compares NTN Buzztime and Pulmatrix's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NTN Buzztime-61.42%-162.54%-49.94%
Pulmatrix-166.00%-147.81%-56.43%

Summary

Pulmatrix beats NTN Buzztime on 7 of the 12 factors compared between the two stocks.

NTN Buzztime (NYSEAMERICAN:NTN) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap consumer discretionary companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Insider and Institutional Ownership

6.3% of NTN Buzztime shares are owned by institutional investors. Comparatively, 0.7% of Monopar Therapeutics shares are owned by institutional investors. 24.2% of NTN Buzztime shares are owned by insiders. Comparatively, 48.4% of Monopar Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares NTN Buzztime and Monopar Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NTN Buzztime$19.81 million0.97$-2,050,000.00N/AN/A
Monopar TherapeuticsN/AN/A$-4,220,000.00($0.45)-12.47

NTN Buzztime has higher revenue and earnings than Monopar Therapeutics.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for NTN Buzztime and Monopar Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NTN Buzztime0000N/A
Monopar Therapeutics00203.00

Monopar Therapeutics has a consensus target price of $30.00, indicating a potential upside of 434.76%. Given Monopar Therapeutics' higher probable upside, analysts plainly believe Monopar Therapeutics is more favorable than NTN Buzztime.

Profitability

This table compares NTN Buzztime and Monopar Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NTN Buzztime-61.42%-162.54%-49.94%
Monopar TherapeuticsN/A-42.84%-40.98%

Summary

Monopar Therapeutics beats NTN Buzztime on 6 of the 10 factors compared between the two stocks.

NTN Buzztime (NYSEAMERICAN:NTN) and GT Biopharma (OTCMKTS:GTBP) are both small-cap consumer discretionary companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, analyst recommendations, profitability, earnings and risk.

Institutional and Insider Ownership

6.3% of NTN Buzztime shares are owned by institutional investors. 24.2% of NTN Buzztime shares are owned by insiders. Comparatively, 4.5% of GT Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings for NTN Buzztime and GT Biopharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NTN Buzztime0000N/A
GT Biopharma00103.00

GT Biopharma has a consensus price target of $25.00, indicating a potential upside of 139.46%. Given GT Biopharma's higher possible upside, analysts clearly believe GT Biopharma is more favorable than NTN Buzztime.

Volatility & Risk

NTN Buzztime has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Comparatively, GT Biopharma has a beta of 0.06, suggesting that its share price is 94% less volatile than the S&P 500.

Earnings and Valuation

This table compares NTN Buzztime and GT Biopharma's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NTN Buzztime$19.81 million0.97$-2,050,000.00N/AN/A
GT BiopharmaN/AN/A$-38,650,000.00N/AN/A

NTN Buzztime has higher revenue and earnings than GT Biopharma.

Profitability

This table compares NTN Buzztime and GT Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NTN Buzztime-61.42%-162.54%-49.94%
GT BiopharmaN/AN/A-1,837.51%

Summary

NTN Buzztime beats GT Biopharma on 6 of the 10 factors compared between the two stocks.

NTN Buzztime (NYSEAMERICAN:NTN) and AzurRx BioPharma (NASDAQ:AZRX) are both small-cap consumer discretionary companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, analyst recommendations, dividends and profitability.

Analyst Recommendations

This is a summary of current ratings and recommmendations for NTN Buzztime and AzurRx BioPharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NTN Buzztime0000N/A
AzurRx BioPharma01302.75

AzurRx BioPharma has a consensus target price of $3.50, indicating a potential upside of 276.34%. Given AzurRx BioPharma's higher possible upside, analysts clearly believe AzurRx BioPharma is more favorable than NTN Buzztime.

Risk and Volatility

NTN Buzztime has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500. Comparatively, AzurRx BioPharma has a beta of 1.81, meaning that its share price is 81% more volatile than the S&P 500.

Institutional and Insider Ownership

6.3% of NTN Buzztime shares are held by institutional investors. Comparatively, 5.1% of AzurRx BioPharma shares are held by institutional investors. 24.2% of NTN Buzztime shares are held by insiders. Comparatively, 7.3% of AzurRx BioPharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares NTN Buzztime and AzurRx BioPharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NTN Buzztime-61.42%-162.54%-49.94%
AzurRx BioPharmaN/A-316.41%-162.80%

Earnings and Valuation

This table compares NTN Buzztime and AzurRx BioPharma's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NTN Buzztime$19.81 million0.97$-2,050,000.00N/AN/A
AzurRx BioPharmaN/AN/A$-15,180,000.00N/AN/A

NTN Buzztime has higher revenue and earnings than AzurRx BioPharma.

Summary

NTN Buzztime beats AzurRx BioPharma on 6 of the 10 factors compared between the two stocks.


NTN Buzztime Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
EDSA
Edesa Biotech
0.9$5.70+0.5%$75.12 million$330,000.00-7.70
Cellectar Biosciences logo
CLRB
Cellectar Biosciences
1.4$1.48+4.1%$74.75 millionN/A-1.28Gap Down
Pulmatrix logo
PULM
Pulmatrix
1.3$1.29+2.3%$72.56 million$7.91 million-1.70News Coverage
Monopar Therapeutics logo
MNPR
Monopar Therapeutics
1.5$5.61+2.1%$70.50 millionN/A-8.77
GT Biopharma logo
GTBP
GT Biopharma
1.2$10.44+15.8%$70.14 millionN/A0.00High Trading Volume
News Coverage
Gap Up
AzurRx BioPharma logo
AZRX
AzurRx BioPharma
1.4$0.93+3.2%$69.23 millionN/A0.00Gap Down
Aeterna Zentaris logo
AEZS
Aeterna Zentaris
0.6$1.10+0.9%$68.95 million$530,000.00-6.11
Purple Biotech logo
PPBT
Purple Biotech
0.6$4.35+1.8%$68.40 million$1 million-1.45
CNTTF
CannTrust
0.9N/AN/A$67.40 million$15.96 million137.18High Trading Volume
Ocuphire Pharma logo
OCUP
Ocuphire Pharma
2.0$5.94+3.0%$64.92 millionN/A0.00High Trading Volume
News Coverage
Gap Up
Aerpio Pharmaceuticals logo
ARPO
Aerpio Pharmaceuticals
1.2$1.35+2.2%$63.87 million$20.16 million-13.50
Catabasis Pharmaceuticals logo
CATB
Catabasis Pharmaceuticals
1.6$2.71+2.6%$63.46 millionN/A-1.27Gap Down
Aridis Pharmaceuticals logo
ARDS
Aridis Pharmaceuticals
1.2$5.60+0.9%$62.88 million$1.02 million-2.26Analyst Report
News Coverage
AGE
AgeX Therapeutics
0.5$1.63+0.6%$61.83 million$1.73 million-5.43
Evoke Pharma logo
EVOK
Evoke Pharma
1.4$1.91+0.5%$61.83 millionN/A-3.90News Coverage
Salarius Pharmaceuticals logo
SLRX
Salarius Pharmaceuticals
1.5$1.38+3.6%$61.73 million$3.46 million-0.65Analyst Upgrade
Gap Down
Soligenix logo
SNGX
Soligenix
1.4$1.51+2.0%$60.43 million$4.60 million-2.44Analyst Revision
Qualigen Therapeutics logo
QLGN
Qualigen Therapeutics
1.1$2.60+0.8%$59.96 millionN/A-0.52
RZLTD
Rezolute
0.0$6.89+1.0%$58 millionN/A0.00High Trading Volume
PRED
Predictive Technology Group
0.1$0.18+8.0%$57.64 million$24.44 million0.00Gap Up
Rezolute logo
RZLT
Rezolute
0.6$6.89+1.0%$57.55 millionN/A0.00
ELTP
Elite Pharmaceuticals
0.5$0.06+3.4%$57.47 million$18 million0.00
Neos Therapeutics logo
NEOS
Neos Therapeutics
0.7$1.15+2.6%$57.22 million$64.65 million-2.61Gap Down
Kintara Therapeutics logo
KTRA
Kintara Therapeutics
1.8$1.86+0.0%$56.96 millionN/A-0.93Gap Up
CNS Pharmaceuticals logo
CNSP
CNS Pharmaceuticals
1.4$2.23+2.2%$56.42 millionN/A-7.96
Alimera Sciences logo
ALIM
Alimera Sciences
1.3$9.56+1.5%$55.00 million$53.94 million-12.10
CV Sciences logo
CVSI
CV Sciences
1.3$0.50+6.0%$53.66 million$53.70 million-2.50Gap Up
Newron Pharmaceuticals logo
NWPHF
Newron Pharmaceuticals
0.4$3.00+0.0%$53.55 million$7.88 million-2.36
Cyclacel Pharmaceuticals logo
CYCC
Cyclacel Pharmaceuticals
1.4$7.40+2.2%$52.57 million$150,000.00-1.39
Trevi Therapeutics logo
TRVI
Trevi Therapeutics
1.7$2.61+1.1%$51.98 millionN/A-1.75News Coverage
IntelGenx Technologies logo
IGXT
IntelGenx Technologies
1.2$0.46+4.3%$51.80 million$740,000.00-2.02Gap Up
GHSI
Guardion Health Sciences
0.5$2.12+0.0%$51.79 million$900,000.000.00
APLIF
Appili Therapeutics
1.7$0.82+2.4%$51.66 million$150,000.00-6.33Gap Down
Forward Pharma A/S logo
FWP
Forward Pharma A/S
0.7$7.32+5.1%$49.71 millionN/A0.00
Bio-Path logo
BPTH
Bio-Path
1.5$6.84+1.2%$47.52 millionN/A-2.30Analyst Report
Cumberland Pharmaceuticals logo
CPIX
Cumberland Pharmaceuticals
0.9$3.17+4.1%$47.30 million$47.53 million-14.41News Coverage
Gap Down
RVPH
Reviva Pharmaceuticals
0.2$5.02+1.8%$46.35 millionN/A-10.91Analyst Revision
News Coverage
Gap Down
Bellerophon Therapeutics logo
BLPH
Bellerophon Therapeutics
1.8$4.87+0.4%$46.22 millionN/A-1.47News Coverage
F-star Therapeutics logo
FSTX
F-star Therapeutics
1.8$10.42+2.8%$44.98 millionN/A-1.50Analyst Report
Analyst Revision
News Coverage
Addex Therapeutics logo
ADDXF
Addex Therapeutics
0.6$1.65+0.0%$43.51 millionN/A0.00High Trading Volume
PBLA
Panbela Therapeutics
1.7$4.31+3.2%$43.46 millionN/A0.00Gap Up
Lixte Biotechnology logo
LIXT
Lixte Biotechnology
0.0$3.20+2.8%$43.32 millionN/A0.00
Acer Therapeutics logo
ACER
Acer Therapeutics
1.3$3.02+1.7%$43.22 millionN/A-1.46
Ceapro logo
CRPOF
Ceapro
0.7$0.57+2.2%$43.17 million$9.71 million28.45News Coverage
Gap Down
PRFX
PainReform
1.0$4.23+3.3%$42.56 millionN/A0.00
Histogen logo
HSTO
Histogen
1.6$1.17+4.3%$41.75 million$21.72 million-0.33Gap Down
Adial Pharmaceuticals logo
ADIL
Adial Pharmaceuticals
0.4$2.38+1.7%$41.10 millionN/A-3.22Insider Selling
News Coverage
Can-Fite BioPharma logo
CANF
Can-Fite BioPharma
1.4$2.38+1.3%$40.83 million$2.03 million-1.28
HOTH
Hoth Therapeutics
0.5$1.78+7.3%$40.54 millionN/A0.00Gap Down
CPHI
China Pharma
0.8$0.88+5.7%$40.28 million$10.92 million-1.88Gap Down
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.